EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Methylprednisolone and Endothelial Dysfunction in Cardiac Surgery: A Pilot Randomized Trial

Katarina Winant Halenarova iD, Daniel De Backer iD, Hassane Njimi iD, Fabio Silvio Taccone, Luc Van Obbergh iD

Acta Anaesthesiologica Scandinavica · 2025

DOI: 10.1111/aas.70109 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Acta Anaesthesiologica Scandinavica, 2025. Verfasst von Katarina Winant Halenarova und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care, Erasme Hospital, Hôpitaux Universitaires de Bruxelles, Brussels, Belgium. Hauptthemen laut MEDLINE: Methylprednisolone, Cardiac Surgical Procedures, Endothelium, Vascular. Die Arbeit nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cardiac surgery involving cardiopulmonary bypass (CPB) serves as a clinical model of ischemia–reperfusion injury and endothelial dysfunction. Endothelial injury is often manifested clinically by vasoplegia and microcirculatory disturbances. The administration of a single dose of corticosteroids at the time of anesthesia induction has been hypothesized to exert a protective effect.

Methods

In this parallel‐group, randomized, controlled single‐center trial, patients scheduled for elective cardiac surgery with CPB were assigned to receive intravenous methylprednisolone or placebo at anesthesia induction. The primary outcome was the occurrence of endothelial dysfunction, assessed using flow‐mediated dilation (FMD) during a vascular occlusion test. Secondary outcomes included peripheral tissue reperfusion slope measured by near‐infrared spectroscopy (NIRS StO 2 ) and syndecan‐1 levels, variations of FMD, NIRS StO 2 , and syndecan‐1 over time, and the correlation between the three measurements.

Results

Thirty‐nine patients were assigned to receive either methylprednisolone ( n = 20) or placebo ( n = 20). Maximal post‐CPB median FMD was 5.7% (IQR: 3.4%–7.0%) in the methylprednisolone group and 4.7% (2.2%–6.6%) in the placebo group (difference: 0.60, 95% CI: −1.5 to 2.7; p = 0.57). On the first postoperative day, median FMD was 6.9% (3.6%–9.8%) in the methylprednisolone group and 8.1% (4.3%–11.6%) in the placebo group (difference: −1.0, 95% CI: −3.6 to 1.6; p = 0.46). No other significant differences between groups were observed for other measurements. A significant correlation was found between the severity of FMD alteration and syndecan‐1 levels ( r = 0.21, p = 0.03).

Conclusions

Methylprednisolone did not significantly affect CPB‐associated endothelial dysfunction markers in elective cardiac surgery patients. Nevertheless, a correlation between syndecan‐1 levels and the peak arterial dilation suggests a link between the severity of glycocalyx damage and vascular reactivity. Editorial Comment Glycocalyx damage has been associated with impaired vascular reactivity. This pilot trial assessed methylprednisolone effect on flow‐mediated arterial dilation and also tissue oxygen saturation during a vascular occlusion test as well as syndecan‐1 levels, these in an elective cardiac surgical cohort, to see if a single steroid dose could limit cardiopulmonary bypas‐related endothelial dysfunction. Single steroid dose here did not effect the main outcome, flow mediated areterial dilation, in this cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethylprednisoloneCardiac Surgical ProceduresEndothelium, VascularHumansMalePilot ProjectsFemaleAgedMiddle AgedSyndecan-1Cardiopulmonary BypassDouble-Blind Method

Stichwörter der Autor:innen

cardiac surgerycardiopulmonary bypassendothelial dysfunctionflow‐mediated dilationmicrocirculation

Substanzen

MethylprednisoloneSyndecan-1

Autor:innen und Institutionen

  • Department of Intensive Care, Erasme Hospital, Hôpitaux Universitaires de Bruxelles, Brussels, Belgium.
  • Intensive Care Unit, CHIREC Hospital Group, Université Libre de Bruxelles, Brussels, Belgium.
  • Department of Anesthesia, Erasme Hospital, Hôpitaux Universitaires de Bruxelles, Brussels, Belgium.

ORCID-Profile: Katarina Winant Halenarova, Daniel De Backer, Hassane Njimi, Luc Van Obbergh

Zitieren

APA

Halenarova, K. W., De Backer, D., Njimi, H., Taccone, F. S., & Van Obbergh, L. (2025). Methylprednisolone and Endothelial Dysfunction in Cardiac Surgery: A Pilot Randomized Trial. Acta Anaesthesiologica Scandinavica. https://doi.org/10.1111/aas.70109

Vancouver

Halenarova KW, De Backer D, Njimi H, Taccone FS, Van Obbergh L. Methylprednisolone and Endothelial Dysfunction in Cardiac Surgery: A Pilot Randomized Trial. Acta Anaesthesiologica Scandinavica. 2025. doi:10.1111/aas.70109

BibTeX
@article{Halenarova2025,
  author = {Halenarova, Katarina Winant and De Backer, Daniel and Njimi, Hassane and Taccone, Fabio Silvio and Van Obbergh, Luc},
  title = {Methylprednisolone and Endothelial Dysfunction in Cardiac Surgery: A Pilot Randomized Trial},
  journal = {Acta Anaesthesiologica Scandinavica},
  year = {2025},
  doi = {10.1111/aas.70109}
}
Kostenlos starten →